Market Overview

J.P. Morgan Reiterates Neutral Rating on Bristol Myers Squibb Co.

Share:
Related BMY
Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma
AVEO Reaches Enrollment Target in Pivotal Tivozanib Study

In a report published Monday, J.P. Morgan & Co. reiterated its Neutral rating on Bristol Myers Squibb Co. (NYSE: BMY).

J.P. Morgan noted, “Maintain Neutral rating. We continue to view pipeline progression as the key driver for BMY shares and see a number of important events in 2013 including the launch of Eliquis, longer-term data on the company's PD-1 program as well as CV outcomes data for Onglyza. That said, we believe current valuation adequately reflects this with the stock trading at 18x trough 2013E EPS and remain Neutral on BMY shares.”

Bristol Myers Squibb Co. closed on Friday at $31.90.

Latest Ratings for BMY

DateFirmActionFromTo
May 2017BMO CapitalDowngradesMarket PerformUnderperform
Dec 2016JefferiesUpgradesHoldBuy
Oct 2016Hilliard LyonsUpgradesNeutralLong-Term Buy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Reiteration Analyst Ratings

 

Related Articles (BMY)

View Comments and Join the Discussion!